Medera Presents Late-Breaking Data from First-In-Human Gene Therapy Trial for Heart Failure with Preserved Ejection Fraction at American Heart Association Scientific Sessions 2025
Medera is a clinical-stage biopharmaceutical company focused on targeting difficult-to-treat and currently incurable diseases by developing a range of next-generation therapeutics. Medera operates via ...
Gene Therapy Reverses Diabetes Heart Failure
Scientists have reversed diabetic heart failure with a genetic therapy in mice and a miniature human hearts made from stem ...
Medscape
Gene Therapy Shows Lipid Improvement but Raises Flags
A CRISPR-based gene therapy showed improvement in lipids in difficult-to-treat patients, but one study raised flags after a ...
New gene discovery can help repair heart damage from heart attack or heart failure
Your heart will not just give you fear and uncertainty after a heart attack; it can leave scar tissue that stiffens your ...
Medera Announces First Patient Dosed in Phase 2 Portion of MUSIC-HFrEF Phase 1b/2 Trial Evaluating SRD-001 Gene Therapy for Heart Failure with Reduced Ejection Fraction
Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing next-generation therapeutics, today announced that the first patient has ...
CRISPR updates early-stage trial data for heart disease therapy
CRISPR Therapeutics (CRSP) posts new data from an early stage trial for CTX310, an in vivo gene editing therapy for heart ...
Can a One-Time Gene Therapy Lower Cholesterol?
Researchers report early but encouraging results on an experimental gene-editing treatment for high cholesterol.